Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Evaluating Pulse Oximetry Bias in Children With Darker Skin Pigmentation
In this prospective study, the investigators will enroll 154 children with arterial lines to determine the accuracy of pulse oximeters in children with darker skin pigmentation. Studies in adults suggest pulse oximeters may overestimate the true level of oxygenation in the blood as measured directly by co-oximetry. However, pediatric data are relatively limited. This study, which is funded by the FDA through the Stanford-UCSF (University of California San Francisco) Clinical Excellence in Regulatory Science and Innovation (CERSI) Program, will determine if the error/bias is associated with skin pigmentation and whether the error falls outside FDA standards. The broader purpose of the study is to work toward eliminating health disparities.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- diagnostic test: Pulse Oximeter (Massimo)
Eligibility
Inclusion Criteria:
1. Age ≤21 years of age
2. Requires arterial vascular access as part of routine clinical care
3. Patient or legally authorized representative (LAR) willing to provide written informed
consent
Exclusion Criteria:
1. Anemia defined as a Hgb <8 g/dL
2. Methemoglobinemia or carbon monoxide poisoning where the SpO2 is known to be
inaccurate
3. Skin condition, such as epidermolysis bullosa, where pulse oximetry not expected to be
accurate, or application of skin probes is medically inadvisable
4. Non-pulsatile patients (e.g., left ventricular assist device (LVAD), extracorporeal
membrane oxygenation (ECMO)
5. Lack of informed consent
Ages Eligible for Study
N/A - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Christopher Almond, MD
650-724-2439
I'm interested
Psoriasis Clinical Trials
Evaluating Pulse Oximetry Bias in Children With Darker Skin Pigmentation
In this prospective study, the investigators will enroll 154 children with arterial lines to determine the accuracy of pulse oximeters in children with darker skin pigmentation. Studies in adults suggest pulse oximeters may overestimate the true level of oxygenation in the blood as measured directly by co-oximetry. However, pediatric data are relatively limited. This study, which is funded by the FDA through the Stanford-UCSF (University of California San Francisco) Clinical Excellence in Regulatory Science and Innovation (CERSI) Program, will determine if the error/bias is associated with skin pigmentation and whether the error falls outside FDA standards. The broader purpose of the study is to work toward eliminating health disparities.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- diagnostic test: Pulse Oximeter (Massimo)
Eligibility
Inclusion Criteria:
1. Age ≤21 years of age
2. Requires arterial vascular access as part of routine clinical care
3. Patient or legally authorized representative (LAR) willing to provide written informed
consent
Exclusion Criteria:
1. Anemia defined as a Hgb <8 g/dL
2. Methemoglobinemia or carbon monoxide poisoning where the SpO2 is known to be
inaccurate
3. Skin condition, such as epidermolysis bullosa, where pulse oximetry not expected to be
accurate, or application of skin probes is medically inadvisable
4. Non-pulsatile patients (e.g., left ventricular assist device (LVAD), extracorporeal
membrane oxygenation (ECMO)
5. Lack of informed consent
Ages Eligible for Study
N/A - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Christopher Almond, MD
650-724-2439
I'm interested
Dermatology Clinical Trials
Evaluating Pulse Oximetry Bias in Children With Darker Skin Pigmentation
In this prospective study, the investigators will enroll 154 children with arterial lines to determine the accuracy of pulse oximeters in children with darker skin pigmentation. Studies in adults suggest pulse oximeters may overestimate the true level of oxygenation in the blood as measured directly by co-oximetry. However, pediatric data are relatively limited. This study, which is funded by the FDA through the Stanford-UCSF (University of California San Francisco) Clinical Excellence in Regulatory Science and Innovation (CERSI) Program, will determine if the error/bias is associated with skin pigmentation and whether the error falls outside FDA standards. The broader purpose of the study is to work toward eliminating health disparities.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- diagnostic test: Pulse Oximeter (Massimo)
Eligibility
Inclusion Criteria:
1. Age ≤21 years of age
2. Requires arterial vascular access as part of routine clinical care
3. Patient or legally authorized representative (LAR) willing to provide written informed
consent
Exclusion Criteria:
1. Anemia defined as a Hgb <8 g/dL
2. Methemoglobinemia or carbon monoxide poisoning where the SpO2 is known to be
inaccurate
3. Skin condition, such as epidermolysis bullosa, where pulse oximetry not expected to be
accurate, or application of skin probes is medically inadvisable
4. Non-pulsatile patients (e.g., left ventricular assist device (LVAD), extracorporeal
membrane oxygenation (ECMO)
5. Lack of informed consent
Ages Eligible for Study
N/A - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Christopher Almond, MD
650-724-2439
I'm interested
Pediatric Dermatology Clinical Trials
Evaluating Pulse Oximetry Bias in Children With Darker Skin Pigmentation
In this prospective study, the investigators will enroll 154 children with arterial lines to determine the accuracy of pulse oximeters in children with darker skin pigmentation. Studies in adults suggest pulse oximeters may overestimate the true level of oxygenation in the blood as measured directly by co-oximetry. However, pediatric data are relatively limited. This study, which is funded by the FDA through the Stanford-UCSF (University of California San Francisco) Clinical Excellence in Regulatory Science and Innovation (CERSI) Program, will determine if the error/bias is associated with skin pigmentation and whether the error falls outside FDA standards. The broader purpose of the study is to work toward eliminating health disparities.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- diagnostic test: Pulse Oximeter (Massimo)
Eligibility
Inclusion Criteria:
1. Age ≤21 years of age
2. Requires arterial vascular access as part of routine clinical care
3. Patient or legally authorized representative (LAR) willing to provide written informed
consent
Exclusion Criteria:
1. Anemia defined as a Hgb <8 g/dL
2. Methemoglobinemia or carbon monoxide poisoning where the SpO2 is known to be
inaccurate
3. Skin condition, such as epidermolysis bullosa, where pulse oximetry not expected to be
accurate, or application of skin probes is medically inadvisable
4. Non-pulsatile patients (e.g., left ventricular assist device (LVAD), extracorporeal
membrane oxygenation (ECMO)
5. Lack of informed consent
Ages Eligible for Study
N/A - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Christopher Almond, MD
650-724-2439
I'm interested
Evaluating Pulse Oximetry Bias in Children With Darker Skin Pigmentation
In this prospective study, the investigators will enroll 154 children with arterial lines to determine the accuracy of pulse oximeters in children with darker skin pigmentation. Studies in adults suggest pulse oximeters may overestimate the true level of oxygenation in the blood as measured directly by co-oximetry. However, pediatric data are relatively limited. This study, which is funded by the FDA through the Stanford-UCSF (University of California San Francisco) Clinical Excellence in Regulatory Science and Innovation (CERSI) Program, will determine if the error/bias is associated with skin pigmentation and whether the error falls outside FDA standards. The broader purpose of the study is to work toward eliminating health disparities.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- diagnostic test: Pulse Oximeter (Massimo)
Eligibility
Inclusion Criteria:
1. Age ≤21 years of age
2. Requires arterial vascular access as part of routine clinical care
3. Patient or legally authorized representative (LAR) willing to provide written informed
consent
Exclusion Criteria:
1. Anemia defined as a Hgb <8 g/dL
2. Methemoglobinemia or carbon monoxide poisoning where the SpO2 is known to be
inaccurate
3. Skin condition, such as epidermolysis bullosa, where pulse oximetry not expected to be
accurate, or application of skin probes is medically inadvisable
4. Non-pulsatile patients (e.g., left ventricular assist device (LVAD), extracorporeal
membrane oxygenation (ECMO)
5. Lack of informed consent
Ages Eligible for Study
N/A - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Christopher Almond, MD
650-724-2439
I'm interested
Evaluating Pulse Oximetry Bias in Children With Darker Skin Pigmentation
In this prospective study, the investigators will enroll 154 children with arterial lines to determine the accuracy of pulse oximeters in children with darker skin pigmentation. Studies in adults suggest pulse oximeters may overestimate the true level of oxygenation in the blood as measured directly by co-oximetry. However, pediatric data are relatively limited. This study, which is funded by the FDA through the Stanford-UCSF (University of California San Francisco) Clinical Excellence in Regulatory Science and Innovation (CERSI) Program, will determine if the error/bias is associated with skin pigmentation and whether the error falls outside FDA standards. The broader purpose of the study is to work toward eliminating health disparities.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- diagnostic test: Pulse Oximeter (Massimo)
Eligibility
Inclusion Criteria:
1. Age ≤21 years of age
2. Requires arterial vascular access as part of routine clinical care
3. Patient or legally authorized representative (LAR) willing to provide written informed
consent
Exclusion Criteria:
1. Anemia defined as a Hgb <8 g/dL
2. Methemoglobinemia or carbon monoxide poisoning where the SpO2 is known to be
inaccurate
3. Skin condition, such as epidermolysis bullosa, where pulse oximetry not expected to be
accurate, or application of skin probes is medically inadvisable
4. Non-pulsatile patients (e.g., left ventricular assist device (LVAD), extracorporeal
membrane oxygenation (ECMO)
5. Lack of informed consent
Ages Eligible for Study
N/A - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Christopher Almond, MD
650-724-2439
I'm interested